Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.

2.

Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.

Wang JQ, Wang B, Lei ZN, Teng QX, Li JY, Zhang W, Ji N, Cai CY, Ma LY, Liu HM, Chen ZS.

Eur J Pharmacol. 2019 Nov 15;863:172611. doi: 10.1016/j.ejphar.2019.172611. Epub 2019 Aug 30.

PMID:
31476282
3.

Revisiting mTOR inhibitors as anticancer agents.

Teng QX, Ashar YV, Gupta P, Gadee E, Fan YF, Reznik SE, Wurpel JND, Chen ZS.

Drug Discov Today. 2019 Oct;24(10):2086-2095. doi: 10.1016/j.drudis.2019.05.030. Epub 2019 Jun 4. Review.

PMID:
31173912
4.

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS.

Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9.

PMID:
31078601
5.

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Teng QX, Chen ZS, Kong D, Yang DH.

Front Pharmacol. 2018 Oct 30;9:1236. doi: 10.3389/fphar.2018.01236. eCollection 2018.

6.

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells.

Zhang W, Fan YF, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P, Chen ZS.

Front Pharmacol. 2018 Oct 9;9:1097. doi: 10.3389/fphar.2018.01097. eCollection 2018.

Supplemental Content

Loading ...
Support Center